Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Epistemonikos ID: be2c9067d0622bdd340b935bfcc5d0c6836fd861
First added on: May 10, 2024